Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Deffered Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $7.6 million as the latest value for Q1 2026.

  • Quarterly Non-Current Deffered Revenue fell 68.6% to $7.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Feb 2026, down 68.6% year-over-year, with the annual reading at $10.0 million for FY2025, 61.8% down from the prior year.
  • Non-Current Deffered Revenue for Q1 2026 was $7.6 million at Nurix Therapeutics, down from $10.0 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $55.4 million in Q1 2022, with the low at $7.6 million in Q1 2026.
  • Average Non-Current Deffered Revenue over 5 years is $28.4 million, with a median of $26.2 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 75.35% in 2023, then surged 191.5% in 2024.
  • Over 5 years, Non-Current Deffered Revenue stood at $36.0 million in 2022, then grew by 25.15% to $45.0 million in 2023, then tumbled by 41.79% to $26.2 million in 2024, then plummeted by 61.8% to $10.0 million in 2025, then decreased by 24.23% to $7.6 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $7.6 million, $10.0 million, and $15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.